Next-Generation CAR T-Cell Therapies Reshaping Non-Hodgkin's Lymphoma Treatment Market Through 2034 | DelveInsight Insights

DelveInsight's report titled "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive evaluation of CAR T-cell therapy in Non-Hodgkin's lymphoma. It covers both historical and projected epidemiological data, along with market trends across the United States, EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.

The newly published healthcare forecast study delivers a detailed assessment of CAR T-cell therapy in Non-Hodgkin's lymphoma, presenting valuable insights into revenue patterns, disease prevalence, and treatment advancements. The report thoroughly examines key statistics, including current and future market size, while also evaluating the effectiveness and progress of emerging therapies.

Additionally, it explores the clinical trial landscape, highlighting ongoing and upcoming studies expected to influence the future treatment paradigm. Overall, the report serves as a vital resource for understanding evolving market dynamics and therapeutic developments in this space.

To gain deeper insights into market outlook, drug adoption, treatment approaches, and epidemiological trends, visit: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Report:
• The CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market is projected to expand at a notable CAGR throughout the forecast period (2020-2034).
• The total CAR T-Cell Therapy for Non-Hodgkin's lymphoma Treatment Market Size in the United States was around USD 1,200 million in 2023, expected to rise by 2034.
• In November 2024, Lyell Immunopharma, Inc. announced that early clinical findings from its Phase 1-2 IMPT-314 study in large B-cell lymphoma will be presented at the 66th ASH Annual Meeting in San Diego (December 7-10, 2024). IMPT-314 is a dual-targeting CD19/CD20 CAR T-cell therapy designed for aggressive B-cell NHL patients.
• In May 2024, Verismo Therapeutics received FDA IND clearance for SynKIR-310 targeting relapsed/refractory B-cell NHL.
• In March 2024, Bristol Myers Squibb reported FDA approval of BREYANZI as the first CAR T-cell therapy indicated for adult patients with relapsed/refractory CLL or SLL.
• Leading CAR T-Cell Therapy for Non-Hodgkin's lymphoma companies in this domain include Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science, Juno Therapeutics, Gilead Sciences, Novartis, BMS, Allogene Therapeutics, Miltenyi Biomedicine, Autolus Therapeutics, and Tessa Therapeutics, among others.
• Key CAR T-Cell Therapy for Non-Hodgkin's lymphoma therapies include Human CD19-Targeted T Cells Injection, Mosunetuzumab, IM19 CAR-T Cells, lisocabtagene maraleucel, YESCARTA, KYMRIAH, BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel (YTB323), Zamtocabtagene autoleucel, AUTO4, CD30.CAR-T, and others.
• The CAR T-Cell Therapy for Non-Hodgkin's lymphoma market is expected to witness substantial growth due to rising disease prevalence and increasing awareness. The introduction of pipeline therapies at various development stages is anticipated to significantly transform market dynamics.
• DelveInsight estimates indicate that approximately 125,900 NHL patients in the 7MM were eligible for CAR-T therapy in 2023.
• Diffuse Large B-Cell Lymphoma (DLBCL) remains the most prevalent subtype in the EU4 and UK, with nearly 32,400 reported cases in 2023.
• Japan recorded approximately 23,700 new NHL cases across selected subtypes in 2023.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Overview
CAR (Chimeric Antigen Receptor) T-cell therapy represents a cutting-edge treatment approach for certain forms of Non-Hodgkin's lymphoma. This therapy involves engineering a patient's own T-cells to express receptors that specifically target malignant B-cells. Once modified, these cells are reinfused into the patient, where they identify and eliminate cancerous cells. This approach has demonstrated strong efficacy, particularly in relapsed or refractory NHL cases, and is widely regarded as a breakthrough in immuno-oncology due to its targeted mechanism and utilization of the body's immune defenses.

Request a free sample report:
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Epidemiology
The epidemiology section outlines past, present, and future disease trends across the seven major markets (7MM) from 2020 to 2034. It identifies the factors influencing these trends through analysis of multiple studies and expert opinions. Additionally, it provides a detailed breakdown of diagnosed patient populations and anticipated future developments.

CAR T-Cell Therapy for Non-Hodgkin's lymphoma Epidemiology Segmentation:
The report delivers epidemiological insights segmented as follows:
• Overall prevalence of CAR T-cell therapy-eligible NHL cases
• Prevalence categorized by disease severity
• Gender-specific prevalence distribution
• Diagnosed cases across episodic and chronic conditions

Download the epidemiology forecast report here:
https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

CAR T-Cell Therapy for Non-Hodgkin's lymphoma Drug Uptake and Pipeline Development
The drug uptake section evaluates adoption rates of recently launched therapies as well as those anticipated during the forecast timeline. It includes analysis of drug-specific market penetration, patient adoption trends, and revenue performance.
Furthermore, the therapeutic assessment identifies drugs gaining rapid traction and explains the factors contributing to their widespread use. Comparative analysis based on market share is also included.
The report also explores pipeline development activities, offering insights into investigational therapies across different stages. It highlights key players, recent collaborations, mergers, acquisitions, licensing deals, and patent-related developments shaping the future of CAR T-cell therapies.

Key CAR T-Cell Therapy for Non-Hodgkin's lymphoma Therapies and Companies:
• Human CD19 Targeted T Cells Injection - Hrain Biotechnology
• Mosunetuzumab - Lazaros Lekakis
• IM19 CAR-T Cells - Beijing Immunochina Medical Science
• Lisocabtagene maraleucel - Juno Therapeutics
• YESCARTA - Gilead Sciences
• KYMRIAH - Novartis
• BREYANZI - BMS
• Cemacabtagene ansegedleucel - Allogene Therapeutics
• Rapcabtagene autoleucel (YTB323) - Novartis
• Zamtocabtagene autoleucel - Miltenyi Biomedicine
• AUTO4 - Autolus Therapeutics
• CD30.CAR-T - Tessa Therapeutics
Explore more about the CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment landscape:
https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market Drivers
• Advancements in immunotherapy technologies
• High effectiveness in relapsed/refractory NHL cases
• Increasing number of FDA approvals
• Rising incidence of Non-Hodgkin's lymphoma
• Continuous clinical research and trials
• Favorable patient outcomes

CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market Challenges
• Expensive treatment procedures
• Limited accessibility in certain regions
• Complex and time-intensive manufacturing processes
• Risk of adverse effects
• Reimbursement-related hurdles
• Uncertainty regarding long-term safety and efficacy

Scope of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key CAR T-Cell Therapy for Non-Hodgkin's lymphoma Companies: Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science, Juno Therapeutics, Gilead Sciences, Novartis, BMS, Allogene Therapeutics, Miltenyi Biomedicine, Autolus Therapeutics, Tessa Therapeutics, and others
• Key CAR T-Cell Therapy for Non-Hodgkin's lymphoma Therapies: Human CD19Targeted T Cells Injection, Mosunetuzumab, IM19 CAR-T Cells, lisocabtagene maraleucel, YESCARTA, KYMRIAH, BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel (YTB323), Zamtocabtagene autoleucel, AUTO4, CD30.CAR-T, and others
• CAR T-Cell Therapy for Non-Hodgkin's lymphoma Therapeutic Assessment: CAR T-Cell Therapy for Non-Hodgkin's lymphoma current marketed and CAR T-Cell Therapy for Non-Hodgkin's lymphoma emerging therapies
• CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market Dynamics: CAR T-Cell Therapy for Non-Hodgkin's lymphoma market drivers and CAR T-Cell Therapy for Non-Hodgkin's lymphoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• CAR T-Cell Therapy for Non-Hodgkin's lymphoma Unmet Needs, KOL's views, Analyst's views, CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market Access and Reimbursement

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.